Blue Cross and Blue Shield of Nebraska (BCBSNE) is preparing the Prescription Drug Data Collection (RxDC) reporting required under the Consolidated Appropriations Act (CAA), which must be submitted to the Centers for Medicare & Medicaid Services (CMS) by June 1, 2026. This reporting applies to all groups covered by BCBSNE during calendar year 2025.
What this means for your group:
Fully insured groups
BCBSNE already has all required data needed to complete RxDC reporting on your behalf. No action is required from you at this time.
ASO (self-funded) groups
Additional information is required. Your Account Executive sent a survey that must be completed to support RxDC reporting.
BCBSNE completes this reporting at no cost to you—we simply need timely participation where applicable.
Important Deadline
The RxDC survey must be completed no later than March 31, 2026.
The CAA requires health plans to submit data related to prescription drugs and overall health care spending to the U.S. Department of Health and Human Services (HHS), Department of Labor, and Department of the Treasury. To support this requirement, ASO groups are asked to complete the survey by the deadline noted above.
If you have questions or need assistance locating your survey, please contact your BCBSNE Account Executive.
Prime Therapeutics LLC is an independent company providing pharmacy benefit management services for Blue Cross and Blue Shield of Nebraska, an independent licensee of the Blue Cross Blue Shield Association. Prime Therapeutics has an ownership interest in AllianceRx Walgreens Prime, a central specialty pharmacy and mail service company.
